Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
976 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05223413 | REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs(RESILIENCE) | recruiting | N/A | 608 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIOTHER | 6 | Sep 18, 2025 | clinicaltrials |
| NCT05354427 | Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients(CLP-10095) | completed | — | 175 | BioProtectINDUSTRY |
| 2 |
| Sep 16, 2025 |
| clinicaltrials |
| NCT03778931 | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(EMERALD) | completed | Phase 3 | 478 | Stemline Therapeutics, Inc.INDUSTRY | 17 | Sep 15, 2025 | clinicaltrials |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer(AMEERA-5) | terminated | Phase 3 | 1,068 | SanofiINDUSTRY | 30 | Sep 11, 2025 | clinicaltrials |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer(VITAL) | completed | Phase 3 | 913 | SanofiINDUSTRY | 32 | Sep 10, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT04098146 | Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis | recruiting | — | 300 | AO Innovation Translation CenterOTHER | 8 | Sep 4, 2025 | clinicaltrials |
| NCT02748460 | Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting(Premium) | completed | — | 1,527 | PregLem SAINDUSTRY | 16 | Sep 2, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT05411666 | Maintenance Optimization of the Fully Implanted Venous Catheter(OTIMACAT) | recruiting | N/A | 176 | Clinical Academic Center (2CA-Braga)OTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02904577 | Indolent Non Follicular Lymphomas Prognostic Project | completed | — | 370 | Fondazione Italiana Linfomi - ETSOTHER | 6 | Aug 8, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera(VERIFY) | active not recruiting | Phase 3 | 293 | Protagonist Therapeutics, Inc.INDUSTRY | 20 | Aug 7, 2025 | clinicaltrials |
| NCT00002462 | RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease | active not recruiting | Phase 3 | 615 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 5, 2025 | clinicaltrials |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,649 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 5, 2025 | clinicaltrials |
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 31, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | CelgeneINDUSTRY | 23 | Jul 8, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT03045406 | Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer(CARAVAGGIO) | completed | Phase 3 | 1,170 | Fadoi Foundation, ItalyOTHER | 11 | Jun 24, 2025 | clinicaltrials |
| NCT04420598 | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease(DEBBRAH) | completed | Phase 2 | 41 | MedSIROTHER | 2 | Jun 24, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT04006405 | AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC(AUR87A) | completed | — | 280 | ElyptaINDUSTRY | 11 | Jun 15, 2025 | clinicaltrials |
| NCT03072238 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer(IPATential150) | completed | Phase 3 | 1,101 | Hoffmann-La RocheINDUSTRY | 26 | Jun 6, 2025 | clinicaltrials |
| NCT04394624 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)(CARMEN-LC04) | terminated | Phase 2 | 31 | SanofiINDUSTRY | 6 | Jun 6, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT06997861 | Medication Review Improves Pain Management and Quality of Life in Chronic Pain | completed | N/A | 20 | Polytechnic Institute of PortoOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06986213 | Heart Pillow - Chemoteraphy(Hepi_Qt) | enrolling by invitation | N/A | 60 | José Manuel Afonso MoreiraOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT06972160 | Intervention Project to Increase Adherence to Colorectal Cancer Screening in Barcelos/Esposende | recruiting | N/A | 1,038 | Local Health Unit Barcelos/Esposende, Public Health UnitOTHER_GOV | 1 | May 14, 2025 | clinicaltrials |
| NCT01526369 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer(TH V THL) | completed | Phase 3 | 75 | Cancer Trials IrelandNETWORK | 8 | May 9, 2025 | clinicaltrials |
| NCT05383352 | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas(SIRACUSA) | completed | Phase 1 | 177 | IpsenINDUSTRY | 7 | Apr 30, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
| NCT03161353 | Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.(PHERGain) | active not recruiting | Phase 2 | 377 | MedSIROTHER | 7 | Apr 23, 2025 | clinicaltrials |
| NCT06915610 | Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program(JANUS) | enrolling by invitation | N/A | 5,700 | Instituto de Saude Publica da Universidade do PortoOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06852833 | One-day Mind Programme for Women With Breast Cancer | active not recruiting | N/A | 40 | University of CoimbraOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT01853826 | An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | completed | Phase 3 | 481 | Boehringer IngelheimINDUSTRY | 11 | Apr 11, 2025 | clinicaltrials |
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT05976815 | Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients(KEYMOVE) | recruiting | N/A | 86 | University Institute of MaiaOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894290 | International Cardiac Amyloidosis Registry(ICAR) | recruiting | — | 300 | Leiden University Medical CenterOTHER | 5 | Mar 25, 2025 | clinicaltrials |
| NCT06396611 | Exercise As Intervention in Chronic Lymphocytic Leukemia(ADRENALINE) | active not recruiting | N/A | 11 | Universidade do PortoOTHER | 1 | Mar 19, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials